Company news

Karyopharm Therapeutics Inc. news in 2026

Karyopharm Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.

View company

Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis

November 17, 2026

Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)

November 4, 2026

Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future

November 2, 2026

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2026

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

August 31, 2026

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

August 13, 2026

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

August 10, 2026

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

July 30, 2026

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

July 30, 2026

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

June 3, 2026

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

June 2, 2026

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 1, 2026

Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

June 1, 2026

Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference

May 28, 2026

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment

May 13, 2026

Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026

May 7, 2026

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

March 23, 2026

Karyopharm Announces $30 Million Private Placement with RA Capital

March 23, 2026

Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress

February 12, 2026

Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

February 5, 2026

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)

February 3, 2026

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2026

Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026

January 12, 2026

Calls in 2026

Decks in 2026